Organization · Venture Capital
Trinity Innovation Bioventure Singapore
Trinity Innovation Bioventure Singapore (TIBS) is a biomed venture capital fund based in Singapore, focusing on early to mid-stage biotechnology investments in the Asian markets. The firm specializes in innovative therapeutics across various sectors, including oncology and RNA therapeutics.
Overview
What Trinity Innovation Bioventure Singapore does
What Trinity Innovation Bioventure Singapore is
Trinity Innovation Bioventure Singapore (TIBS) is a biomed venture capital fund based in Singapore, focusing on early to mid-stage biotechnology investments in the Asian markets. The firm specializes in innovative therapeutics across various sectors, including oncology and RNA therapeutics.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2018
- Approximate age
- About 8 years
- Structured capabilities
- Funder
- Last reviewed
- May 5, 2026
Official channels
Find Trinity Innovation Bioventure Singapore elsewhere
Open the official website or a supported primary organization account.
Capability profile
Trinity Innovation Bioventure Singapore as a funder
Investment thesis
Trinity Innovation Bioventure Singapore aims to nurture great biomed companies with a focus on Asia, investing in early-to-mid stage biotechnology firms that address unmet medical needs with innovative science.
Focus narrative
TIBS invests in the biomed sector, emphasizing innovation and value creation. The organization has a deep understanding of the Asian markets and aims to identify emerging innovations and opportunities for new drug development, particularly in oncology, RNA therapeutics, and immunotherapy.
Value beyond capital
TIBS adds value to its portfolio companies through its extensive network and expertise in the biomed sector, particularly in navigating the Asian regulatory landscape and facilitating partnerships with major pharmaceutical companies. The firm's team brings deep scientific and commercial expertise, enhancing the growth potential of its investments.
Focus and fit
- Stages
- Seed · Series A · Series B
- Regions
- Asia · Greater China
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- TransThera Sciences
Portfolio context
Notable portfolio companies include: TransThera Sciences: A clinical-stage small molecule biotech for oncology and cardiometabolic diseases, which had a successful IPO in June 2025. Shanghai Argo Biopharmaceutical: Focused on RNAi therapeutics with a multi-program licensing deal with Novartis. Epigenic Therapeutics: Developer of epigenetic medicines, recently raised $60M in Series B funding. Ribo Life Science: Engaged in siRNA therapeutics with collaborations with Boehringer Ingelheim. VelaVigo: A bispecific antibody platform with multiple out-licensing deals.
Common questions
What to know about Trinity Innovation Bioventure Singapore
Upseed classifies Trinity Innovation Bioventure Singapore under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.